Ten new medicines recommended for approval
The committee recommended granting a marketing authorisation for Alhemo (concizumab), a medicine for routine prophylaxis of bleeding in patients with haemophilia A or B with inhibitors, two types of a rare inherited bleeding disorder.
The CHMP adopted positive opinions for two vaccines intended for active immunisation against influenza: Fluad (surface antigen, inactivated, adjuvanted), intended for adults 50 years of age and older, and Flucelvax (surface antigen, inactivated, prepared in cell cultures), for adults and children from two years of age.
Korjuny (catumaxomab) received a positive opinion from the CHMP for the intraperitoneal treatment of malignant ascites, a build-up of fluid containing cancer cells in the abdomen of cancer patients…
